# Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96

> **NCT02133079** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cure&Sure Biotech Co., LTD** · enrollment: 20 (actual)

## Conditions studied

- Liver Cancer
- Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** autologous gp96 vaccination

## Key facts

- **NCT ID:** NCT02133079
- **Lead sponsor:** Cure&Sure Biotech Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2016-11
- **Final completion:** 2019-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133079, "Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02133079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*